PMID- 20193412
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20221207
IS  - 0529-567X (Print)
IS  - 0529-567X (Linking)
VI  - 44
IP  - 12
DP  - 2009 Dec
TI  - [Clinical application of telomerase RNA component gene amplification assay in 
      cervical lesions.].
PG  - 883-6
AB  - OBJECTIVE: To investigate the significance of genomic amplification of the 
      telomerase RNA component (TERC) gene to serve as a genetic biomarker in the 
      screening of cervical lesions. METHODS: A total of 715 cases were recruited, with 
      liquid-based cytology diagnosis as normal (n = 347), atypical squamous cells of 
      undetermined significance (ASCUS, n = 180), atypical squamous cells cannot 
      exclude a high-grade lesion (ASC-H, n = 13), low-grade squamous intraepithelial 
      lesions (LSIL, n = 115), high-grade squamous intraepithelial lesions (HSIL, n = 
      59) and atypical glandular cells (AGC, n = 1). The remaining cervical cells in 
      the cytological preserving fluid were analyzed using a two-color fluorescence in 
      situ hybridization (FISH) probe targeted to chromosome 3q26 containing TERC gene. 
      The TERC gene findings were compared to the cytological and histological detected 
      results, as well as high-risk human papillomavirus (HPV) detected results. 
      RESULTS: Genomic amplification of TERC gene was found in 5.8% of normal 
      specimens, 22.2% of ASCUS, 30.8% of ASC-H, 27.8% of LSIL, 86.4% of HSIL and 1/1 
      of AGC. The positive rate was significantly lower in normal, ASCUS, ASC-H and 
      LSIL compared with HSIL (all P < 0.01). Significantly more cells with genomic 
      amplification of TERC gene were found in cervical intraepithelial lesion (CIN) 
      II-III than CINI (77.8% vs. 9.3%), as well as invasive cervical cancer (96.7% vs. 
      9.3%), both P < 0.01. The rate of TERC gene amplification was higher in HPV 
      positive patients (33.5%) than in HPV negative patients (5.2%, P < 0.01). The 
      sensitivity of TERC gene amplification was significantly higher than that of 
      cytological screening (81.88% vs. 36.96%, P < 0.01) in the differentiation of 
      CINII or higher and CINI or lower diseases, its specificity was higher than 
      high-risk HPV test (93.32% vs. 33.93%, P < 0.01) and positive prediction value 
      (81.29%) was similar with cytological method (86.44%, P > 0.05); but its negative 
      prediction value (93.56%) was lower than HPV test (97.06%, P < 0.05). 
      CONCLUSIONS: The positive rates of TERC gene amplification increased as cervical 
      diseases worsened. TERC gene amplification is related to HPV infection. The gain 
      of chromosome 3q26 in cytological specimens is an effective molecular genetic 
      biomarker in screening of CINII or higher and invasive cervical cancer.
FAU - Jiang, Jing
AU  - Jiang J
AD  - Department of Obstetrics and Gynecology, Peking University People's Hospital, 
      Beijing 100044, China.
FAU - Wei, Li-Hui
AU  - Wei LH
FAU - Wu, Rui-Fang
AU  - Wu RF
FAU - Zhang, Guo
AU  - Zhang G
FAU - Wulan, Na
AU  - Wulan N
FAU - Li, Jing-Ran
AU  - Li JR
FAU - Li, Yi-Bing
AU  - Li YB
FAU - Tu, Zheng
AU  - Tu Z
FAU - Zhou, Yan-Qiu
AU  - Zhou YQ
FAU - Zhao, Yun
AU  - Zhao Y
FAU - Chen, Zhong
AU  - Chen Z
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Fu Chan Ke Za Zhi
JT  - Zhonghua fu chan ke za zhi
JID - 16210370R
SB  - IM
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Uterine Cervical Dysplasia
MH  - Uterine Cervical Neoplasms
EDAT- 2010/03/03 06:00
MHDA- 2016/04/24 06:00
CRDT- 2010/03/03 06:00
PHST- 2010/03/03 06:00 [entrez]
PHST- 2010/03/03 06:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PST - ppublish
SO  - Zhonghua Fu Chan Ke Za Zhi. 2009 Dec;44(12):883-6.